These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37096491)

  • 1. Efficacy, safety, and tolerability of ulotaront (SEP-363856, a trace amine-associated receptor 1 agonist) for the treatment of schizophrenia and other mental disorders: a systematic review of preclinical and clinical trials.
    Le GH; Gillissie ES; Rhee TG; Cao B; Alnefeesi Y; Guo Z; Di Vincenzo JD; Jawad MY; March AM; Ramachandra R; Lui LMW; McIntyre RS
    Expert Opin Investig Drugs; 2023 May; 32(5):401-415. PubMed ID: 37096491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ulotaront: a TAAR1/5-HT1A agonist in clinical development for the treatment of schizophrenia.
    Højlund M; Correll CU
    Expert Opin Investig Drugs; 2022 Dec; 31(12):1279-1290. PubMed ID: 36533396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trace amine-associated receptor 1 (TAAR1) agonism for psychosis: a living systematic review and meta-analysis of human and non-human data.
    Siafis S; Chiocchia V; Macleod MR; Austin C; Homiar A; Tinsdeall F; Friedrich C; Ramage FJ; Kennett J; Nomura N; Maksym O; Rutigliano G; Vano LJ; McCutcheon RA; Gilbert D; Ostinelli EG; Stansfield C; Dehdarirad H; Juma DO; Wright S; Simple O; Elugbadebo O; Tonia T; Mantas I; Howes OD; Furukawa TA; Milligan L; Moreno C; Elliott JH; Hastings J; Thomas J; Michie S; Sena ES; Seedat S; Egger M; Potts J; Cipriani A; Salanti G; Leucht S
    Wellcome Open Res; 2024; 9():182. PubMed ID: 39036710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ulotaront, a novel TAAR1 agonist with 5-HT1A agonist activity, lacks abuse liability and attenuates cocaine cue-induced relapse in rats.
    Synan C; Bowen C; Heal DJ; Froger-Colléaux C; Beardsley PM; Dedic N; Hopkins SC; Campbell U; Koblan KS
    Drug Alcohol Depend; 2022 Feb; 231():109261. PubMed ID: 35033729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia.
    Achtyes ED; Hopkins SC; Dedic N; Dworak H; Zeni C; Koblan K
    Eur Arch Psychiatry Clin Neurosci; 2023 Oct; 273(7):1543-1556. PubMed ID: 37165101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unlocking the Therapeutic Potential of Ulotaront as a Trace Amine-Associated Receptor 1 Agonist for Neuropsychiatric Disorders.
    Kuvarzin SR; Sukhanov I; Onokhin K; Zakharov K; Gainetdinov RR
    Biomedicines; 2023 Jul; 11(7):. PubMed ID: 37509616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vitro Comparison of Ulotaront (SEP-363856) and Ralmitaront (RO6889450): Two TAAR1 Agonist Candidate Antipsychotics.
    Ågren R; Betari N; Saarinen M; Zeberg H; Svenningsson P; Sahlholm K
    Int J Neuropsychopharmacol; 2023 Sep; 26(9):599-606. PubMed ID: 37549917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A New Treatment Paradigm: Targeting Trace Amine-Associated Receptor 1 (TAAR1) in Schizophrenia.
    Kane JM
    J Clin Psychopharmacol; 2022 Sep-Oct 01; 42(5 Suppl 1):S1-S13. PubMed ID: 36099402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TAAR1 agonist ulotaront delays gastric emptying of solids in patients with schizophrenia and concurrent metabolic syndrome with prediabetes.
    Milanović S; Dedic N; Lew R; Burton D; Koblan KS; Camilleri M; Hopkins SC
    Diabetes Obes Metab; 2024 Jun; 26(6):2466-2475. PubMed ID: 38533552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies.
    Dedic N; Dworak H; Zeni C; Rutigliano G; Howes OD
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34947997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trace Amine-Associated Receptor 1 as a Target for the Development of New Antipsychotics: Current Status of Research and Future Directions.
    Kantrowitz JT
    CNS Drugs; 2021 Nov; 35(11):1153-1161. PubMed ID: 34655036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Depicting Safety Profile of TAAR1 Agonist Ulotaront Relative to Reactions Anticipated for a Dopamine D2-Based Pharmacological Class in FAERS.
    Hopkins SC; Ogirala A; Worden M; Koblan KS
    Clin Drug Investig; 2021 Dec; 41(12):1067-1073. PubMed ID: 34751928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vitro ADME and Preclinical Pharmacokinetics of Ulotaront, a TAAR1/5-HT
    Xiao G; Chen YL; Dedic N; Xie L; Koblan KS; Galluppi GR
    Pharm Res; 2022 May; 39(5):837-850. PubMed ID: 35484370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ulotaront: A TAAR1 Agonist for the Treatment of Schizophrenia.
    Heffernan MLR; Herman LW; Brown S; Jones PG; Shao L; Hewitt MC; Campbell JE; Dedic N; Hopkins SC; Koblan KS; Xie L
    ACS Med Chem Lett; 2022 Jan; 13(1):92-98. PubMed ID: 35047111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with the novel TAAR1 agonist ulotaront is associated with reductions in quantitative polysomnographic REM sleep without atonia in healthy human subjects: Results of a post-hoc analysis.
    Feemster JC; Westerland SM; Gossard TR; Steele TA; Timm PC; Jagielski JT; Strainis E; McCarter SJ; Hopkins SC; Koblan KS; St Louis EK
    Sleep Med; 2023 Jan; 101():578-586. PubMed ID: 36584503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TAAR1 agonist ulotaront modulates striatal and hippocampal glutamate function in a state-dependent manner.
    Yang SM; Ghoshal A; Hubbard JM; Gackière F; Teyssié R; Neale SA; Hopkins SC; Koblan KS; Bristow LJ; Dedic N
    Neuropsychopharmacology; 2024 Jun; 49(7):1091-1103. PubMed ID: 38110609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study.
    Correll CU; Koblan KS; Hopkins SC; Li Y; Heather Dworak ; Goldman R; Loebel A
    NPJ Schizophr; 2021 Dec; 7(1):63. PubMed ID: 34887427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TAAR1 agonists improve glycemic control, reduce body weight and modulate neurocircuits governing energy balance and feeding.
    Dedic N; Wang L; Hajos-Korcsok E; Hecksher-Sørensen J; Roostalu U; Vickers SP; Wu S; Anacker C; Synan C; Jones PG; Milanovic S; Hopkins SC; Bristow LJ; Koblan KS
    Mol Metab; 2024 Feb; 80():101883. PubMed ID: 38237896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modafinil for people with schizophrenia or related disorders.
    Ortiz-Orendain J; Covarrubias-Castillo SA; Vazquez-Alvarez AO; Castiello-de Obeso S; Arias Quiñones GE; Seegers M; Colunga-Lozano LE
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD008661. PubMed ID: 31828767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.